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Summary
Objective: To investigate the efficacy and tolerability of a 3-month duration, twice a-year, intermittent treatment with oral chondroitin sulfate
(CS) in knee osteoarthritis (OA) patients.
Design: A total of 120 patients with symptomatic knee OA were randomized into two groups receiving either 800 mg CS or placebo (PBO)
per day for two periods of 3 months during 1 year. Primary efficacy outcome was Lequesne’s algo-functional index (AFI); secondary outcome
parameters included VAS, walking time, global judgment, and paracetamol consumption. Radiological progression was assessed by
automatic measurement of medial femoro-tibial joint space width on weight-bearing X-rays of both knees. Clinical and biological tolerability
was assessed.
Results: One hundred and ten of 120 patients were included in the ITT analysis. AFI decreased significantly by 36% in the CS group after
1 year as compared to 23% in the PBO group. Similar results were found for the secondary outcomes parameters. Radiological progression
at month 12 showed significantly decreased joint space width in the PBO group with no change in the CS group. Tolerability was good with
only minor adverse events identically observed in both groups.
Conclusion: This study provides evidences that oral CS decreased pain and improved knee function. The 3-month intermittent administration
of 800 mg/day of oral CS twice a year does support the prolonged effect known with symptom-modifying agents for OA. The inhibitory
effect of CS on the radiological progression of the medial femoro-tibial joint space narrowing could suggest further evidence of its
structure-modifying properties in knee OA.
© 2004 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Introduction
Osteoarthritis (OA) is the most common form of arthritis
in developed countries. The current treatment of OA is
not aimed at cure but mainly at palliative management
and includes physical, pharmacological and surgical
approaches. Most drug treatments have been developed to
alleviate the symptoms of OA, mainly by reducing inflam-
matory processes and pain. There are two categories of
symptomatic drugs for OA; the first are non-specific and
rapidly acting such as analgesics and non-steroidal anti-
inflammatory drugs (NSAIDs) whereas the second are
specific and slow acting with delayed onset of action
(symptom-modifying agents). The rationale for using
symptom-modifying drugs such as chondroitin sulfate (CS)
as a treatment for OA disease was in part empirical based
on the observation that CS decreased with aging and OA.
Nevertheless, recent studies do support its administration
such as the fact that the sulfation pattern of CS was found
to be significantly altered in both OA cartilage, plasma
and synovial fluid1,2. Indeed it appears that exogenous
chondroitin sulfate is absorbed as a high molecular mass
polysaccharide together with CS derivatives originating
from a partial depolymerization and/or desulfatation3–5.
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Some studies regarding symptom-modifying agents were
recently reviewed in two meta-analyses including both
CS and glucosamine sulfate6,7. Most clinical studies per-
formed with CS were of short duration, generally 3–6
months8–11. We previously reported a randomized, double-
blind 1-year duration controlled pilot study that was per-
formed on a small cohort of 42 patients12. The patients
were treated orally with 800 mg CS or with a placebo
administered daily for 1 year. This limited study confirmed
that CS was well-tolerated, significantly reduced pain and
increased overall mobility capacity. In addition, in agree-
ment with the American College of Rheumatology (ACR)
recommendations13,14, we also studied the potential
structure-modifying effect of the drug12. As with other
symptom-modifying agents like glucosamine sulfate or
hyaluronan, it is suggested that CS has a prolonged effect,
which would justify an intermittent administration of the
drug for the treatment of OA8. As a consequence, the
authors set up a 1-year duration randomized, placebo-
controlled study with two 3-month intermittent treatment
periods with CS in patients with femoro-tibial OA. The
primary aim of this study was to test the symptomatic
efficacy of the drug, whereas the secondary aims were to
assess both additional clinical parameters, radiological
progression of knee OA using an automated measurement
of the medial femoro-tibial joint space and measure some
biochemical markers of bone and joint metabolism (this
later part to be published in a separate article).
Methods
PATIENTS
A total of 120 patients of both gender, aged 40 and over
and suffering from mono- or bi-lateral, clinically sympto-
matic idiopathic knee OA according to ACR criteria13,14
(patients suffering from knee pain and at least one of the
three following criteria: age >40 years, stiffness <30 min,
crepitus, as well as osteophytes) were enrolled between
February 1996 and June 1998 in this multicenter study.
Moreover only patients with a Kellgren and Lawrence
radiological score of I–III with a minimum 25% remaining
medial femoro-tibial joint space upon entry were selected.
Incorporated patients were randomly allocated in equal
numbers to one of the two treatment groups: chondroitin
sulfate (CS) or placebo (PBO). All patients with other
inflammatory joint diseases or systemic conditions affecting
or involving the joints were excluded from the study. In
addition, patients with the following conditions were also
excluded from the study: primary or secondary neoplasias,
bone metabolic diseases, and/or other metabolic or sys-
temic diseases, patients undergoing various treatments
such as intra-articular steroids, NSAIDs, symptom-
modifying agents or bone-oriented therapies such as flu-
orides, bisphosphonates, calcitonin or patients under
hormonal substitution taken within 3 months before the
beginning of the study (wash-out period) were also
excluded. The above treatments were also forbidden
during the whole study duration.
All patients received complete information from the study
physician before entering the trial and signed an informed
consent sheet. The study protocol followed the rules of
Good Clinical Practice and the Declaration of Helsinki
and was reviewed and approved by multiple Independent
Ethics Committees before the study began.
TREATMENT REGIMEN
The study design was double-blinded, placebo-
controlled and all selected patients randomly allocated in
one of two treatment groups. Patients in the CS group
received Condrosulf® sachets (IBSA, Lugano, Switzerland)
containing 800 mg of chondroitin 4&6 sulfate at a dose of 1
sachet/day taken every evening with a glass of water.
Condrosulf® is a prescription drug containing highly purified
chondroitin 4&6 sulfate of bovine origin in a concentration
not inferior to 95%. Patients in the PBO group received
placebo sachets containing 800 mg of vehicle administered
on the same time schedule as for the CS group. Placebo
and Condrosulf® sachets were packed in white anonymous
sachets of identical appearance containing granules having
the same aspect, odor and flavor.
The treatment was administered intermittently from entry
to month 3 and between months 6 and 9. Patients of both
groups received no treatment between months 3–6 and
9–12. Treatment compliance was established by asking the
patients to return the remaining drugs supply. Each subject
was free to take his own medication for co-existing dis-
eases or conditions during the study with the exception
of NSAIDs, symptom-modifying agents, steroids (oral or
parenteral), bone-oriented therapies, (fluorides, bisphos-
phonates, calcitonin and hormonal substitution). Patients
were free to take paracetamol (maximum 4 g/day) as
rescue medication if needed, but they had to report the total
amount of tablets taken in the daily diary. Study patients are
required to stop the analgesic treatment (paracetamol) 24 h
before every visit. The same physician evaluated each
individual subject every 3 months throughout the study.
Treatments were assigned in blocks of six according to a
computer generated randomization list. Investigators were
provided with sealed envelopes, each marked with the
corresponding patient number and containing the random-
ization code assigned to that patient. These envelopes
were to be opened only in the event of an emergency.
OUTCOME MEASUREMENTS FOR EFFICACY
According to WHO/ILAR Guidelines for the evaluation of
SYSADOA13, the following criteria were measured upon
entry and during the study:
+ The primary efficacy outcome criteria was the
Lequesne’s algofunctional index (AFI)15 at the end of
the study. The AFI is a standardized and validated
clinical instrument to evaluate pain and function in knee
or hip OA patients. In patients with bilateral knee OA,
the most symptomatic knee was selected as the study
target knee.
+ The secondary efficacy outcome criteria included
the following additional clinical and radiological
measurements.
The degree of spontaneous joint pain as assessed by the
Huskisson’s visual analogue scale (VAS) on a continuous
scale of 0–100 mm16, the walking time evaluated as the
minimum time in seconds necessary to perform a 20-m
walk on a flat track course, the global judgment of efficacy
as recorded by the patient and the physician on a semi-
quantitative 4-point ordinal scale and the overall paraceta-
mol consumption evaluating the number of tablets taken
between two control visits.
Standard antero-posterior X-rays of the knees were
performed in weight-bearing monopodal position upon
entry and after 12 months of follow-up. Patients stood with
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their knee fully extended and the film cassette was
positioned as close as possible to the posterior surface of
the joint. Patients were provided with hand support if
required. The outline of the foot was drawn on a sheet of
paper taped on the floor and the foot map was used to
reposition the joint at the following examination. The X-ray
film cassette was held in a vertical film holder with a
film-to-focus distance of 110 cm. Radiographs of the knees
were taken by the same trained observer at entry and at 12
months and used the reference atlas for the Kellgren and
Lawrence qualitative score17. The medial femoro-tibial joint
space width (JSW) was measured for both right and
left knees by one observer blinded to the radiographic
sequence with an image analysis computer (Mediscan®,
Hologic, Inc.) according to a previously published
method18. Briefly, the method includes a digitization of the
X-ray and an automatic determination of a constant part of
the medial femoro-tibial joint space. Within the demarcated
area, the joint space contours are delineated by the
operator. In this study, no target knee was defined at the
beginning. The joint space surface area (JSSA), the mean
joint space width (MeJSW) and the interbone distance at
the narrowest point of the joint (minimum joint space width
[MiJSW]) are automatically calculated. The reproducibility
of the method has already been reported18–21.
SAFETY AND TOLERABILITY OUTCOMES
Tolerability was assessed during overall study period at
3-month intervals by both patients and investigators using
a 4-point verbal semi-quantitative judgment score. Any
adverse event occurring during the treatment period
was reported in the CRF. In addition, clinical laboratory
evaluation was performed at the same times to assess
the biological safety; these examinations included the
determination of blood ESR, CRP, Hb, Ht, WBC, platelets
and of the serum levels of bilirubin, urea and creatinine.
STATISTICAL METHODS AND DETERMINATION OF THE SAMPLE
SIZE
The sample size population calculation was estimated
according to previous clinical experience with oral CS
treatment. Based on the hypothesis that the mean value of
the Lequesne’s index reduction after 1 year is by 40% for
the Condrosulf® group and 20% for the Placebo group,
considering a standard deviation of about 30% of the basal
value for each group and performing the one way analysis
of variance (in assuming =0.05, two-tailed, and =0.20,
that is a power of 80%), it would be necessary to analyze at
least 80 patients (40 per group). Considering a drop out
rate of about 30%, it would be necessary to enroll 120
patients (60 per group).
A descriptive statistical analysis including frequency of
occurrence, mean±standard deviation (SD), minimum and
maximum for all parameters was performed. The level of
significance of the results was set at a P value=0.05. Age,
weight and height were analyzed according to the Student
t-test for unpaired data. Gender, concomitant or previous
treatments, adverse events, concomitant treatments and
dropouts were analyzed according to Yates corrected 2 for
2×2 tables.
The efficacy analysis was performed for the ITT popu-
lation and the last observation carried forward (LOCF)
method was used to replace missing values for the 26 drop
out patients.
Pain levels and consumption of paracetamol were
analyzed according to the Mann–Whitney U-test for non-
parametric data.
Huskisson VAS, walking time, Lequesne’s index and
biological safety parameters were analyzed by ANOVA for
repeated measures. For these variables, multiple compari-
sons were calculated according to Bonferroni’s correction
equation.
The knee radiological parameters have been analyzed
by a standard Student’s t-test and by ANOVA for repeated
measures (the two knees of each subject were analyzed
independently). Only the ‘completers’ with radiological data
for one or two knees were included in this analysis. In
addition, we used the analysis of the variation for each
patient using the generalized estimating equations method
(GEEM)22,23. In the case of our radiological data, GEEM
analysis allows to consider that the two knees of each
patient are not independent, and no target knee has to be
chosen. A total of 84 patients completed the 1-year study,
but six of them did not perform X-rays at month 12 for
personal reasons, therefore radiological evaluations were
only available for 78 patients (39 in each treatment group).
Compliance analysis was performed with the non-
parametric Mann–Whitney U-test. Judgment of efficacy and
tolerability expressed by both physician and patient were
analyzed according to the linear trend test. The statistical
analysis of the results was carried out at the INSERM Unit
521 of the Gustave Roussy Institute, University of Paris XI,
Villejuif, France.
Results
A total of 120 patients were randomized in the study. A
total of 10 patients (six CS and four PBO) were lost to
follow-up before month 3 (second control visit). Since they
did not take any dose of treatment and did not report any
data at the following control visit, they were consequently
not included in the ITT analysis. Therefore, the 110 remain-
ing patients (54 CS and 56 PBO) were included in the
intent-to-treat statistical analysis (Fig. 1). A comparison of
the baseline characteristics upon entry did not show any
significant differences between both CS and PBO groups
(Table I). A total of 26 patients (11 CS and 15 PBO) dropped
out of the study between months 3 and 12 because
of inefficacy, absence of compliance, increasing pain or
various side effects. No statistically significant difference
was shown between both groups. At the end of the study, at
12 months, the number of patients completing the study in
the CS group was 43 and 41 in the PBO group.
PRIMARY EFFICACY OUTCOME CRITERIA
At entry, the mean score of the Lequesne’s algo-
functional index (AFI), chosen as the primary outcome
efficacy parameter, was not statistically different between
both treatment groups: 9.0±2.8 in the CS group vs 9.1±3.2
in the PBO group. In the CS group, the AFI was decreased
by 24, 25, 34 and 36%, at months 3, 6, 9 and 12,
respectively. In the PBO group the mean AFI score showed
less variations and was reduced by a total of 23% after 12
months (Table II). However, in both groups (CS and PBO),
the mean decrease of AFI was statistically significant
at each time point within each treatment group vs the
mean basal value. An analysis of variance for repeated
measures showed significant differences at month 9 and 12
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between the CS and the PBO groups, P<0.05 and P<0.01,
respectively (Fig. 2).
SECONDARY EFFICACY OUTCOME CRITERIA
Regarding the second outcome efficacy parameters, at
entry into the study, levels of spontaneous pain assessed
by the Huskisson VAS were not significantly different:
58.8±15.5 mm in the CS group vs. 61.1±19 mm in the
PBO group (Table II). The intensity of pain decreased
respectively by 42% at month 9 and 12 in the CS group vs.
25% in the PBO group. Analysis of variance for multiple
comparisons showed a significant difference between both
treatment groups at month 9 and 12, P<0.05.
The mean walking time showed no statistically significant
difference between groups at baseline (24.5±22.7 sec in
the CS group vs. 22.8±7.5 sec in the PBO group). A
statistically significant reduction in the mean walking time
Randomized patients
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|
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n=6
Patients with no data after the first visit
n=10
PBO
n=4
|
CS
n=54 ----------
Evaluated patients as ITT
n=110 -------------
PBO
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|
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n=11 ----------
Dropouts
n=26 -------------
PBO
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|
CS
n=43 ----------
Per protocol population
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Fig. 1. Patient disposition and study course.
Table I
Characteristics of patients at entry (mean±SD)*
Group CS (n=54) PBO (n=56) P (between
groups)
Age (years) 63.2±9.1 63.7±8.1 NS
Gender (M/F) 11/43 10/46 NS
Weight (kg) 76.8±15.8 76.4±13.8 NS
K&L score
(0/1/2/3/4)
(0/7/32/15/0) (0/6/33/17/0) NS
Huskisson VAS
(mm)
58.8±15.5 61.1±19.0 NS
Lequesne’s AFI 9.0±2.8 9.1±3.2 NS
Walking time (s) 24.5±22.7 22.8±7.5 NS
Symptom duration
(months)
50.1 52.4 NS
*Abbreviations: CS=chondroitin sulfate; PBO=placebo;
VAS=Huskisson visual analogue scale; AFI: Lequesne’s algo-
functional index; K&L=Kellgren & Lawrence.
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was observed in the CS group vs. the PBO group as of
month 6 onwards (p < 0.05) and still improved with time
until month 12 (Table II). The overall reduction in the CS
group was 18% vs. 0.5% in the PBO group.
Both the physicians’ and patients’ overall efficacy
assessment was very similar and significantly in favor of
the CS group after respectively 6, 9 and 12 month obser-
vation periods (p < 0.01). At the end of the study by month
12, a total of 52% of the physicians’ and patients’ reported
a global assessment of efficacy as “no effect” or “fair” in the
PBO group vs. 11% in the CS group. In sharp contrast, the
physicians’ and patients’ overall efficacy evaluation was
reported as “good” and “very good” in 89% of the CS
patients as compared to 13% “very good” results and 36%
reported “good” results in the PBO group.
During the first month of treatment, the mean consump-
tion of paracetamol tablets was equivalent in the two
groups (21.6±26.7 in the CS group vs. 22.0±24.2 in the
PBO group). In the following periods, between months 1–3,
3–6, 6–9 and 9–12, the mean paracetamol consumption
was always significantly greater in the PBO group (P<0.05)
as compared with the CS group (25.8±37.0 in the CS group
vs 55.5±68.1 in the PBO group at month 12).
The investigational drugs returned at each control visit,
were considered to reflect the compliance with the treat-
ment. No significant difference in the compliance with the
Table II
Efficacy results (mean±SD): intention-to-treat analysis
Evaluation parameters Control visits (month)
0 3 6 9 12
AFI
CS (n=54) 9.0±2.8 6.8±3.6 6.7±3.5 6.0±3.8 5.8±3.6
* **
PBO (n=56) 9.1±3.2 7.4±4.2 7.5±4.0 7.0±3.9 7.0±3.9
VAS (mm)
CS (n=54) 58.8±15.5 42.9±23.2 40.5±23.9 34.0±26.4 34.3±27.4
* *
PBO (n=56) 61.1±19.0 49.1±24.5 47.6±26.9 46.1±27.2 45.8±27.6
Walking time (s)
CS (n=54) 24.5±22.7 21.4±9.0 21.5±9.4 20.9±8.0 20.1±6.8
* * *
PBO (n=56) 22.8±7.5 22.4±8.3 23.1±8.5 22.7±7.5 22.7±7.7
*P<0.05.
**P<0.01. ANOVA test between groups. CS=chondroitin sulfate; PBO=placebo; VAS=Huskisson visual analogue scale; AFI=Lequesne’s
algo-functional index.
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Fig. 2. Lequesne’s algo-functional index (AFI) and Husskisson visual analogue score for pain (VAS) in delta %.
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treatment was observed between groups (mean returned
tablets±SD at control visit month 3: CS group: 4.4±6.4;
PBO group 4.3±7.7 corresponding to about 93% com-
pliance for both groups; at control visit month 9: CS group:
2.1±3.6; PBO group 2.0±4.5 corresponding to about 98%
compliance for both groups).
Upon entry, the Kellgren and Lawrence (KL) radiological
qualitative score was not significantly different between
both CS (mean±SD: 2.28±1.09) and the PBO (mean±SD:
2.36±1.09) groups (Table I). At the end of the study period,
the mean KL score was unchanged (2.29±1.02 in the CS
group vs 2.45±1.06 in the PBO group). A quantitative
radiological evaluation was also performed on the knee
X-rays using two successive statistical methodologies. At
first, both right and left knees were analyzed separately and
following variables measured: the joint space surface area
(JSSA), mean joint space width (MeJSW) and minimum
joint space width (MiJSW). Upon entry, these variables
were not significantly different between the CS and PBO
groups. At the end of the study, all three variables were
significantly decreased in the PBO group (P<0.01),
whereas no significant changes could be observed in the
CS group (Table IIIA). Table IIIB shows the results ex-
pressed as mean and difference 95% CI change in JSW in
the different groups, with P values based on t-test analysis.
The generalized estimating equation method (GEEM),
which is an extension of the generalized linear models, was
used as an additional tool to analyze the data. Indeed,
GEEM allows us to treat each patient’s data without having
to pre-select a target knee. This analysis showed that,
as compared to placebo, CS treatment had a significant
role upon the variation of JSSA (0.065±0.031; P=0.03)
and MeJSW (0.031±0.017; P=0.03), but not for MiJSW
(0.028±0.020; P=0.1).
SAFETY/TOLERABILITY EVALUATION
Only minor adverse events (AEs) occurred during this
1-year study. Those possibly related to the treatment were
gastrointestinal (epigastralgia, pyrosis and nausea) and
occurred in both CS and PBO groups with a frequency of
four and six events respectively. Two dropouts (1 CS, 1
PBO) occurred during the study due to epigastralgia, while
one patient of the CS group stopped the treatment after 9
months because of vertigo.
Clinical laboratory evaluations did detect some minor
changes in the serum levels of bilirubin by month 9 and
serum urea levels at months 9 and 12 in the PBO group. No
modifications were observed in any other clinical chemistry
or hematological variables except for an isolated ESR
increase in the PBO group by month 12.
The global assessment of tolerability expressed by both
the patients and the physicians was very similar and no
difference was observed between the two groups except for
a significantly better tolerability score for the CS group after
1 month of treatment.
Discussion
This original study presents the results of a 1-year clinical
trial conducted in knee OA patients receiving oral CS
given on a 3-monthly intermittent basis, twice yearly. Based
upon the present results, the following comments can be
addressed.
At first, this study, specifically powered to assess the
clinical effects of CS on pain and function as a primary
efficacy outcome, is a confirmation of previous results
obtained with oral CS used for the treatment of human
Table IIIA
Evolution of the medial femoro-tibial joint space narrowing: left+right knees pooled (mean±SD)
Months CS P (t-test) PBO P (t-test) P (ANOVA)
(n=77)* (within group) (n=76)* (within group) (between groups)
Joint space surface area (JSSA) (mm2)
0 68.0±27.2 63.3±24.4 At baseline: NS
NS P<0.01
12 67.8±26.9 58.7±20.9 Evolution: NS
Minimum joint space width (MiJSW) (mm)
0 3.65±1.46 3.54±1.39 At baseline: NS
NS P<0.01
12 3.61±1.51 3.23±1.27 Evolution: P<0.05
Mean joint space width (MeJSW) (mm)
0 4.20±1.51 4.03±1.47 At baseline: NS
NS P<0.01
12 4.20±1.58 3.74±1.28 Evolution: P<0.05
*Only the X-ray of one knee was available for one patient belonging to CS group and for two patients belonging to PBO group.
Table IIIB
Mean and 95% CI change in joint space narrowing
CS (n=77) PBO (n=76) Difference (95% CI) P (t-test)
JSSA (mm2) −0.19 (−3.56 to 3.17) −4.55 (−8.61 to -0.49) 4.36 (−0.19 to 8.91) 0.060
MiJSW (mm) −0.04 (−0.23 to 0.14) −0.32 (−0.57 to −0.07) 0.27 (0.004 to 0.55) 0.047
MeJSW (mm) −0.006 (−0.20 to 0.18) −0.29 (−0.53 to −0.04) 0.28 (0.01 to 0.55) 0.039
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OA8–12,24. Both AFI, VAS, walking time and analgesic
consumption support the fact that CS is a symptom-
modifying agent, which acts with a delayed onset of action
and does improve both the painful symptoms and the
function of knee OA patients13,25,26.
In addition, this trial confirmed that CS administered
orally at a dose of 800 mg/day on an intermittent basis for
three months twice a year does have a prolonged effect.
This specific effect is a characteristic of the symptom-
modifying agents as well as their delayed onset of
activity25,27. These characteristics have already been well
documented and confirmed in previous studies using oral
CS, but administered on a regular daily basis for periods
extending from 3 up to 12 months8,24. The prolonged
therapeutic effect observed in this intermittent study is a
novel element regarding the mode of action of oral CS. A
potential limiting factor of the study could be that the
comparison was performed between both CS and PBO
groups, but did not include a third group of OA patients
receiving a continuous 1-year daily CS treatment.
The third important finding deals with the potential
structure-modifying properties of the compound26. This
effect was previously suggested in one animal study28 and
two clinical studies including patients with knee OA12 and
finger OA29,30. In the knee OA trial12 we found that treat-
ment with CS was also associated, in a group of patients,
with an absence of change of the medial femoro-tibial joint
space width whereas joint space narrowing did occur in the
placebo-treated patients. The femoro-tibial joint space
measurements obtained in this study suggest that CS
treatment might influence the structural progression of
knee OA over 1 year. In addition, GEEM analysis was a
further confirmation of a significant reduction of the femoro-
tibial joint space narrowing due to CS treatment in two out
of three measured radiographic variables. It must be stated
that minimum JSW represents the most sensitive measure-
ment of joint space narrowing, but this is only true in the
case of postero-anterior X-rays of the knee joint where
the tibial plate is horizontal. In our study, the horizontal
positioning of the tibial plate was not checked, but it
was certainly not optimal as the performed X-rays were
antero-posterior. Even if the X-ray procedure would now
be using postero-anterior projection of the knee joint, this
clinical trial nevertheless represents a further validation
for the non-invasive measurement of joint space narrow-
ing using standardized x-rays and digitized automatic
radiographic computerized equipment18,20. As recently
shown with glucosamine sulfate, some symptom-modifying
agents do have interesting chondroprotective properties,
which can be assessed non-invasively by quantitative
radiography31–33.
A controversial issue with oral CS treatment is often
the actual oral absorption of the drug. In a recent study5,
CS (Condrosulf®) was orally administered to 20 healthy
human volunteers, and CS derivatives were extracted and
purified from plasma over 48 h. After oral administration of
Condrosulf®, CS plasma levels increased by more than
200%. Absorption of exogenous CS was also proved by the
actual changes in the composition of CS derived disaccha-
rides in plasma after drug administration as compared to
baseline.
Importantly, the excellent clinical and biological profile
of tolerance of the drug observed in our study did
also confirm the good safety profile of oral chondroitin
sulfate6–10,12,34,35. This tolerability profile might be
decreased by the intake of CS sold as a neutraceutical as
recently reported by Danao-Camara36. As a consequence,
these authors insisted on the necessity of an optimal
source and a high quality of CS needed for human use.
This particular safety trend does also strongly support the
conduct of future larger and longer chondroprotection
trials37.
Conclusion
This study supports the evidence that oral CS of bovine
origin and high pharmaceutical quality (Condrosulf®) is a
well-tolerated drug, which is effective in reducing pain and
improving function in patients suffering from symptomatic
knee OA. The intermittent treatment schedule of 800 mg/
day for 3 months, twice a year could certainly be recom-
mended for patients presenting with low and/or medium
grade knee OA based upon our clinical results and the
observed prolonged therapeutic effect of the drug. In
addition, our results on those OA patients who completed
the trial might support the hypothesis of earlier studies and
present additional arguments for CS also to be considered
as a structure-modifying drug for OA. Regarding this par-
ticular issue, results of longer duration and larger trials
should ultimately provide the clues regarding the effective-
ness of CS as a structure-modifying drug for the treatment
of knee OA.
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